The main finding of the study was that weekly treatments of ExA for a duration of 6 weeks after the induction of diabetes improves cognitive impairment, insulin resistance, and hepatic steatosis via the activation of GLP-1/GLP-1R. The gene discussed is GLP1R; the disease is diabetes mellitus.